Clinical trial phases are tested as a ladder: safety, efficacy, large comparison, then surveillance.
Phases
Phase 0 uses micro-doses. Phase I tests safety and pharmacokinetics in a small group of healthy volunteers (or patients for toxic drugs). Phase II tests efficacy and dosing in a small group of patients. Phase III compares the drug with standard care in large randomized trials. Phase IV is postmarketing surveillance for rare adverse events.
Concepts
Therapeutic index equals toxic dose divided by effective dose; a narrow index needs drug level monitoring (digoxin, lithium, warfarin, aminoglycosides, theophylline). Potency refers to the dose for an effect; efficacy is the maximum effect. Partial agonists have lower efficacy and can act as antagonists.
Regulation
A new drug application follows trials. Generic drugs must be bioequivalent. Black box warnings flag serious risks.
Keep going in pharmacology
- Dose-response curves: agonists, antagonists, potency and efficacy
- Perioperative medicine: risk assessment and complications
- Vasopressors and inotropes: dopamine, norepinephrine, dobutamine and vasopressin
- Antibiotic choice by organism: a quick reference